WO2018143692A1 - Composition pharmaceutique comprenant comme principe actif de la poudre d'écorce primaire d'orme ou de racine d'ulmus davidiana afin de traiter des plaies et de régénérer la peau - Google Patents

Composition pharmaceutique comprenant comme principe actif de la poudre d'écorce primaire d'orme ou de racine d'ulmus davidiana afin de traiter des plaies et de régénérer la peau Download PDF

Info

Publication number
WO2018143692A1
WO2018143692A1 PCT/KR2018/001386 KR2018001386W WO2018143692A1 WO 2018143692 A1 WO2018143692 A1 WO 2018143692A1 KR 2018001386 W KR2018001386 W KR 2018001386W WO 2018143692 A1 WO2018143692 A1 WO 2018143692A1
Authority
WO
WIPO (PCT)
Prior art keywords
powder
skin
composition
root
wound
Prior art date
Application number
PCT/KR2018/001386
Other languages
English (en)
Korean (ko)
Inventor
안미정
신명철
김혜진
박우성
김선여
Original Assignee
경상대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 경상대학교 산학협력단 filed Critical 경상대학교 산학협력단
Publication of WO2018143692A1 publication Critical patent/WO2018143692A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A61K8/022—Powders; Compacted Powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH

Definitions

  • the present invention relates to a composition for regenerating skin containing milk root skin or milk powder skin or an active ingredient thereof.
  • Skin is a tissue that accounts for 15-20% of the body's total mass, providing a barrier against the penetration of harmful substances into the body while maintaining essential chemicals and nutrients in the body and protecting them from the harmful effects of ultraviolet radiation from the sun. do.
  • the skin consists of two layers, the epidermis and the dermis, which can be divided into three layers, including the hypodermis.
  • the epidermis is the outermost layer of skin that is relatively waterproof, protects internal tissues and organs from various traumas, and plays a role in preventing bacteria, viruses, and other foreign substances from entering the body, both physically and immunologically. .
  • Most cells in the epidermis are keratinocytes, starting from cells located in the basal layer in the deepest layer of the epidermis, slowly moving to the epidermal surface with the creation of new keratinocytes, and falling off when they reach the skin surface.
  • the dermis is composed of elastic and fibrous tissues that maintain the skin, and various structures such as nerve endings for sensing various senses, sweat glands for temperature control, various glands including sebaceous glands, and blood vessels for temperature control in the body are located.
  • Collagen one of the major matrix proteins produced by the fibroblasts of the skin, is an important protein that accounts for about 30% of the total weight of biological proteins and forms most organic substances in the skin, tendons, bones and teeth. Most are present in the dermis.
  • Collagen's main functions include mechanical firmness of skin, resistance and adhesion of connective tissue, support of cell adhesion, and induction of cell differentiation. Therefore, collagen plays an important role in wound healing, and by promoting the synthesis of collagen in the damaged epithelium, the wound can be quickly recovered without scars.
  • a wound is a condition in which the living body is damaged and encompasses a pathological condition in which tissues forming the inner or outer surface of the living body, such as skin, muscle, nerve tissue, bone, soft tissue, internal organs, or vascular tissue, are divided or destroyed.
  • Wounds can be broadly divided into closed and open wounds depending on whether the anatomical structure of the skin is maintained, but in general, open windows are a representative type. If the skin remains open at the time of the wound, complications in addition to pain and discomfort increase, so it is important that the open areas heal into tissues similar to the original skin.
  • the wound healing process is largely divided into four stages: inflammation, granulation, epithelialization and fibroplasia.
  • fibroblasts In the inflammatory phase, they activate the necessary cells (fibroblasts, epithelial cells, etc.). Subsequently, in granulation, fibroblasts deposit collagen, which increases collagen and causes wounds to mature. In addition, changes in keratinocytes occur at the wound site, and epidermis thickens and the epithelial cells move from the basal cells below the epidermis to the epidermis, which is called epithelialization. In addition, through the epithelial phase to the fiber proliferation collagen fibers (collagen fibers) to form a collagenous matrix (collageneous matrix) to fill the wound defects, this is done for a long period of time and then healed. Therefore, epithelial cell proliferation and collagen production may be one of the important mechanisms for wound healing.
  • collagen fibers collagen fibers
  • collagenous matrix collagenous matrix
  • the elm tree is a deciduous tree belonging to the family Elmaceae, and the native species of Korea is Ulmus davidiana var. japonica (Rehder) Nakai), elm (Ulmus davidiana Planch per.), Ulmus parvifolia (Ulmus parvifolia Jacq.) or Ulmus macrocarpa Hance, etc., commonly called elm.
  • Ulmus davidiana var. japonica (Rehder) Nakai grows in the vicinity of the country, including the National valley pearl, economic and Hambuk area. Generally it is 15-25 m in height, 50-70 cm in diameter, and the bark is dark brown with longitudinal cracks.
  • the leaves are regenerated, oval or oblong, 3 ⁇ 10 cm long, 2 ⁇ 6 cm wide, with sharp tips, with cogs on the edges, and the surface of the leaves is rough, beautiful, smooth and with hairs on the back veins. have.
  • Flowers are yellowish green flowers on the upper part of the branches before the leaves in April ⁇ May, with 4 stamens, 1 pistil, and the peduncle is very short.
  • Fruits are poaceae, 1.0-1.5 cm long, mature in May-June, with wings.
  • Elm Ulmus davidiana Planch . ) Is classified into other varieties belonging to the same species as elm.
  • Elm trees have dense hairs on the surface of the fruit, while elm trees have no hairs on the fruit or can only be distinguished by their tips.
  • elm In general, elm is known to have anti-inflammatory and anti-cancer activity, and elm root bark has excellent effects on various ulcerative diseases.
  • bark of elm tree In oriental medicine, bark of elm tree is called milky skin and muscle skin is used for the treatment of moisturizing and diuresis.
  • Republic of Korea Patent No. 10-1379657 discloses a pharmaceutical composition for the prevention and treatment of obesity using the ethanol extract of the root skin.
  • the inventors of the present invention while researching a substance that can treat wounds, have excellent water absorption ability to absorb exudates from the roots or milky skin powders, proliferate epidermal and dermal cells, and the wound regeneration effect of the powders than the extracts in animal models. Is more excellent, and in detail, the present invention was completed by confirming that the therapeutic effect of the fine powder is excellent among the roots of the roots or milky skins.
  • the present invention provides a pharmaceutical composition for the treatment of wound comprising powder of the root of the roots or milky skin as an active ingredient.
  • the present invention provides a cosmetic composition for skin regeneration comprising a powder of the roots of the roots or milky skins as an active ingredient.
  • the present invention provides a composition for external application to the skin comprising a powder of root skin or milk white skin as an active ingredient.
  • the present invention provides a method of treating wounds, comprising administering the root skin or milky skin powder to a subject.
  • the present invention provides a use for the use of a pharmaceutical composition comprising the root skin or milky skin powder for the treatment of wounds.
  • the present invention provides a use for using the cosmetic composition comprising the root skin or milk powder skin for skin regeneration.
  • the root skin or milk dermis powder according to the present invention treats wounds by proliferating the epidermis and dermis tissue in cell lines and animal models, so that the composition comprising the powder of dermis or dermal milk as an active ingredient can be usefully used for the treatment of wounds. .
  • Example 1 is a result of observing the root skin powder according to Example 1 of the present invention with a scanning electron microscope (a powder: 355 ⁇ 850 ⁇ m, a powder: 150 ⁇ 355 ⁇ m, semal: 75 ⁇ 150 ⁇ m, fine powder: 75 ⁇ m or less ).
  • Figure 2 is a result of comparing the water absorption according to the particle size of the root skin powder.
  • Figure 3 is a diagram showing the comparison of cytotoxicity results of the root and baekbaekpi to HaCat cell line, a keratinocyte cell line.
  • Figure 4 is a diagram showing the results of a scratch assay (scratch assay) of the root skin and milk milk skin for HaCat cell line.
  • Figure 5 is a diagram showing the results of the scratch analysis of the root and dermis of the dermis fibroblasts NHDF cell line.
  • Figure 6 is a diagram confirming the wound healing effect by the root powder and extract in the animal model (Ctrl: control, Madecassol: positive control).
  • Figure 7 is a graph showing the wound healing effect of the extracts and root extracts in animal models (Ctrl: control, Madecassol: positive control).
  • Figure 8 is the result of the wound treatment effect of Rhizome and Yubaekpi powder in animal model by date (Ctrl: control, Madecassol: positive control).
  • FIG. 9 is a diagram showing the wound treatment effect of each sample of the 2nd and 8th day in the animal model.
  • Figure 10 is a diagram showing the results showing the regeneration effect of the tissue by the root skin powder (Ctrl: control, NED: positive control).
  • FIG 11 is a diagram showing the effect of increasing collagen synthesis by the root skin powder (Ctrl: control, NED: positive control).
  • the present invention provides a composition for skin regeneration comprising a powder (root) of the root of the elm tree (root root) or stem (milk powder).
  • the present invention provides a method of treating wounds, comprising administering the root skin or milky skin powder to a subject.
  • the present invention provides a use for the use of a pharmaceutical composition comprising the root skin or milky skin powder for the treatment of wounds.
  • the elm (elm tree) is Elm (Ulmus davidiana var. japonica (Rehder) Nakai, ulmus davidiana Planch.), Elm ( Ulmus parvifolia Jacq.) or Elm ( Ulmus) macrocarpa Hance).
  • the roots or milky skins may generally be derived from the root or stem of the elm tree.
  • the roots or baekbaekpi may be purchased from the domestic medicinal market, naturally occurring in the valley and mountain areas, or may be grown in a facility managed by the grower, but is not limited thereto.
  • the powder may be obtained by a method of mechanical grinding, lyophilization and grinding or airflow grinding. Specifically, it may be by mechanical grinding.
  • the pulverized powder may be classified by size using a mesh having a specific size of eyes, a centrifugal separator, a capture device of charged particles, or a colloidal facility. According to one embodiment of the invention, the powder may be classified by particle size using a sieve.
  • the particle size of the pulverized powder is preferably 10-850 ⁇ m. Specifically, the thickness may be 355 ⁇ m or less, specifically 150 ⁇ m or less, and more specifically 75 ⁇ m or less.
  • the powder may be to treat a wound.
  • the wound may be any one or more selected from the group consisting of porcelain, cut intestine, fissure, acne, crocus and abrasion, but is not limited thereto.
  • the powder can promote the formation of keratinocytes at the wound site and can propagate skin dermal tissue.
  • the powder may also increase collagen synthesis in the dermis.
  • the powder may be to absorb exudate.
  • the powder may be an external skin preparation or a cosmetic.
  • the present inventors were to break down the roots and milky skins, respectively, to prepare the roots or powdered milk powder and classify by size (see Figure 1).
  • the present inventors confirmed that the milky skin powder does not have a significant difference in cytotoxicity compared to the milky skin extract, and the myrtle skin powder shows a relatively weak cytotoxicity than the root skin extract at high concentration (see FIG. 3).
  • the present inventors show that the powder of the roots or milky skins has a cell regeneration effect in vitro (FIGS. 4 and 5), and the wound regeneration effect of the powder when comparing the wound treatment effect of the powder and the extract in the in vivo experiment using the animal model. It was confirmed that the better (Figs. 6 and 7), in particular, the fine powder among the powder of the roots or milky skin was confirmed to show a therapeutic effect equivalent to or comparable to the conventional wound treatment (Figs. 8 to 11).
  • all four oil-derived skin powders showed significantly higher absorption than commercially available polyurethane wet dressings. It was confirmed that the finer than the fine absorption (see Figure 2). Therefore, root skin or milk powder may be usefully used in the composition for treating wounds.
  • composition of the present invention may comprise a carrier, diluent, excipient or mixtures thereof which are commonly used.
  • Pharmaceutically acceptable carriers can be used as long as they are suitable for delivery of the composition in vivo.
  • the carrier is Merck Index, 13th ed., Merck & Co. Inc., saline, sterile water, Ringer's solution, dextrose solution, maltodextrin solution, glycerol, ethanol or mixtures thereof.
  • conventional additives such as antioxidants, buffers, bacteriostatics, etc. may be added as necessary.
  • compositions of the present invention may be formulated into a parenteral preparation.
  • the parenteral preparations may include suppositories, respiratory inhalation powders, spray aerosols, powders and creams, and the like.
  • the pharmaceutical composition may be directly applied powder, dry adhesion coating, aerosol, dry aerosol, pump spray, medical pressure bandage, film, coated cast bandage, sponge, surgical patch, hemostatic fleece, gauze, dressing agent , Salve, semi-gel, gel, foam, paste, suspension, ointment, emulsion, moldable form, nasal plug, surgical bandage, wound packing, bandage, cotton wool, catheter, optical fiber , Syringes, pessaries, suppositories, liquid or non-aqueous liquid suspension dressings.
  • the composition may be administered in a pharmaceutically effective amount. This may vary depending on the type of disease, the severity, the activity of the drug, the patient's sensitivity to the drug, the time of administration, the route of administration, the duration of treatment, the drug being used simultaneously, and the like.
  • the effective dose of the composition is 0.01 to 300 mg / cm 2 , preferably 10 to 50 mg / cm 2 , it can be administered 1 to 4 times a day.
  • composition of the present invention may be administered alone or in combination with other therapeutic agents.
  • administration may be sequential or simultaneous.
  • the present invention provides a cosmetic composition for skin regeneration comprising a powder of the roots of the roots or milky skins as an active ingredient.
  • the present invention also provides a use of the cosmetic composition comprising the root skin or milky skin powder for use in skin regeneration.
  • the particles of the root or milk powder according to the present invention are as described above.
  • the particle size of the powder is preferably 10-850 ⁇ m.
  • the thickness may be 355 ⁇ m or less, specifically 150 ⁇ m or less, and more specifically 75 ⁇ m or less.
  • the carrier may be animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or Mixtures thereof.
  • the formulation of the cosmetic composition is a powder or a spray, it may include lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or mixtures thereof.
  • it may further include chlorofluorohydrocarbon, propane / butane or dimethyl ether.
  • the carrier may include a solvent, a solvating agent, an emulsifying agent or a mixture thereof.
  • a solvent examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, sorbitan fatty acid ester and the like.
  • the dosage form of the cosmetic composition of the present invention is a suspension
  • a liquid diluent such as water, ethanol or propylene glycol
  • suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxy, bentonite, agar, tragacanth or mixtures thereof.
  • the formulation of the cosmetic composition is a surfactant-containing cleansing
  • the cosmetic composition according to the present invention is an emulsion, cream, lotion, essence, pack, gel, powder, lipstick, makeup base, foundation, lotion, ointment, gel, patch, essence, flexible lotion, nutrition lotion, nutrition cream, massage It may be included in the formulation of creams, essences, eye creams, cleansing foams, cleansing creams, cleansing water, soaps, sprays.
  • the cosmetic composition of the present invention may include antioxidants, stabilizers, solubilizers, humectants, pigments, perfumes, sunscreens, colorants, surfactants or mixtures thereof as auxiliary agents.
  • the auxiliary agent may be used as long as it is a material commonly used in preparing cosmetic compositions.
  • the present invention provides a composition for external application to the skin comprising a powder of root skin or milk white skin as an active ingredient.
  • the particles of the root or milk powder according to the present invention are as described above.
  • the particle size of the powder is preferably 10-850 ⁇ m.
  • the thickness may be 355 ⁇ m or less, specifically 150 ⁇ m or less, and more specifically 75 ⁇ m or less.
  • the external preparation for skin of the present invention may include a pharmaceutically acceptable carrier and excipient.
  • the carrier and excipient may include preservatives, stabilizers, hydrating agents, emulsifiers, buffers and the like.
  • the excipient may be lactose, dextrin, starch, mannitol, sorbitol, glucose, saccharose, microcrystalline cellulose, gelatin, polyvinylpyrrolidone or mixtures thereof.
  • the external skin composition is a skin gel, cream, lotion, powder, foundation, essence, gel, pack, foam cleansing, soap, skin ointment. It may be included in soaps, cleansing oils, powder foundations, emulsion foundations, wax foundations or aerosols, and may be appropriately prepared according to methods well known in the art.
  • Elm Ulmus purchased at Gyeongdong Market davidiana var. 1 kg of root skin of japonica (Rehder) Nakai) was ground using a mechanical grinder. Pulverized root skin powder was sieved to powder (355-850 ⁇ m), medium (150-355 ⁇ m), fine powder (75-150 ⁇ m) or fine powder (75 ⁇ m or less) using a sieve of No. 20, 50, 100 or 200. ).
  • the particle size of each of the root skin powders was compared.
  • Example 1 the powder obtained in Example 1 was weighed by 1mg for each classification, fixed to a pedestal to which double-sided tape was attached, and then coated with platinum (Pt), and then using a scanning electron microscope (JSM-7601F, JEOL). Observation was made at 50 times magnification.
  • the poultry had a large, thin, long twig shape, and the middle and semal were smaller in size and generally rounder.
  • the size of the particles is very small, the size and shape of the particles appeared to be not uniform (Fig. 1).
  • Density and flowability used as physical property indicators of powdery materials were measured for the root skin powder.
  • Example 1 the powder obtained in Example 1 was weighed 0.5g, medium, semal and fine powder 2g each weighed into a 10 mL mass cylinder to measure the volume to obtain a bulk density, 100 times After tapping, the volume was measured again to obtain a tapped density.
  • the values of the Hausner's Ratio which confirms the fluidity due to friction between particles
  • the Carr's Compressibilty Index which indicates particle flowability
  • TD Tapped density
  • the tap density can be used as an indicator that provides information on how homogeneous the particle size is, and the homogeneity of the particles affects the flowability of the powder, which is compared with the CI of each powder. It was confirmed that the particles were homogeneous in the order of> fine powder> seasoning. All of the above powders have a CI value of more than 15%, regardless of particle size, it was confirmed that the flowability of the root skin powder is not good. Since the flowability of the powder is poor, it can be easily processed on the wound site.
  • Example 1 The properties of the root skin powders obtained in Example 1 were compared through the angle of repose analysis widely used to measure the physical properties of the powder.
  • the radius of the cone (r) and the height (h) of the cone was measured when the powder formed by dropping powder dropped on the ground using a glass funnel adjusted to a height of 30 cm from the ground did not change.
  • Example 1-2 the powders were weighed as in Example 1-2, 1 ml of powder and distilled water were added to a 1.8 ml Eppendorf tube, and mixed at room temperature for about 1 hour, followed by 12000 rpm, 10 in a centrifuge (Eppendorf-5417). Centrifuged in min. After removing the supernatant, the weight of the tube containing the sample was weighed and compared with the weight of the tube and the sample before mixing to calculate the weight of the total water absorbed in each powder.
  • Elm Ulmus purchased at Gyeongdong Market davidiana var. 1 kg of milky skin from japonica (Rehder) Nakai) was ground using a mechanical grinder.
  • the ground milk powder is pulverized using sieve of No. 20, 50, 100 or 200, powder (355-850 ⁇ m), medium (150-355 ⁇ m), fine powder (75-150 ⁇ m) or fine powder (75 ⁇ m). Below).
  • HaCaT human keratinocyte
  • the milky skin fine powder obtained in Example 1 and the milky skin fine powder obtained in Example 2 were dissolved in DMSO, respectively, and were filtered and used for experiments.
  • HaCaT cells were then dispensed in a 96-well plate with 4x10 4 cells / ml, and the process to extract, and the fine end of the sample after 24 hours in each of 1, 10, 50 and 100 ⁇ g / ml concentration of the additional 24 hours in a CO 2 incubator for culturing It was.
  • the culture solution was removed, exchanged with PBS, and 0.5 mg / ml of MTT reagent was added thereto, and reacted in a CO 2 incubator for 4 hours.
  • DMSO was added and allowed to stand in a CO 2 incubator for 30 minutes, and then the absorbance was measured at 570 nm.
  • both methanol extract and fine powder did not show significant cytotoxicity at the concentration of 10 ⁇ g / ml or less, but the cell viability was significantly reduced when methanol extract of the myodermis was treated at 100 ⁇ g / ml, whereas Or milky skin extract / micro-treated group was relatively weak cytotoxicity (Fig. 3).
  • Scratch assay was performed to confirm the wound regeneration effect of the root and dermis powder on the keratinocytes constituting the epidermal layer in the skin.
  • HaCaT cell lines were dispensed into 96-well plates at 4 ⁇ 10 cells / ml, and after 24 hours, 500 ⁇ m wide scratches were formed using Wound Maker (Essen Bioscience). After washing the plate formed with scratches with PBS, and treated with methanol extracts and fine powder samples of root and baekbaekpi each 10 ⁇ g / ml, and then using the IncuCyte® (Essen Bioscience) to restore the scratches by cell migration Observed.
  • Wound Maker Essen Bioscience
  • Scratch assay was performed to confirm the wound regeneration effect of dermis and dermis powder on dermis fibroblasts constituting the dermal layer in the skin.
  • NHDF Normal Human Dermal Fibroblasts
  • Rhizome powder in animal model was compared with the extract.
  • the root-derived powder except for the poultry, which is expected to have a low effect was treated to the wound animal model in the following manner.
  • HR-1 albino hairless mice (central laboratory animals) were adjusted to photoperiod at 23 ⁇ 3 ° C., 60 ⁇ 10% humidity, 12 hours day / 12 hours night, and freely ingested diet and drinking water. It was prepared by. The mice, acclimated for 1 week, were divided into 3 mice per group, and the skin on the panniculsus carnosus was removed in a circle 6 mm in diameter to create two symmetrical wounds.
  • the area of the wound was similar or smaller than that of the positive control group, and the damage of the wound area was significantly reduced.
  • the rate at which the wound area decreases was slow.
  • the area of the wound area did not decrease.
  • the micromalgam treatment group showed a small level of difference in the treatment effect of the individual and showed a certain level of therapeutic effect (Fig. 6). And 7).
  • the root skin powder showed an excellent wound healing effect in the animal model than the root bark extract.
  • the wound regeneration effect according to the particle size of the root skin or milk powder in the animal model was analyzed.
  • the dermal regeneration effect by the dermis powder of the present invention was confirmed by H & E staining.
  • the root powder, semal and fine powder were applied to the wound portion of the mouse, and the untreated group, NED treated group and methanol extract treated group were used as controls.
  • NED treatment group was used to prepare a liquid formulation dissolved in 0.1% in a mixed solvent of ethanol, propylene glycol and water (50:20:30, v / v), methanol extract treatment group was used in the method described in Experimental Example 2 Was prepared using.
  • Animal models treated for 7 days were sacrificed by cervical dislocation method, and tissues of the wounds were collected. The collected tissue was fixed to a paraffin film and cut into 5 ⁇ thickness to obtain a section. Hematoxylin & Eosin (H & E) dye was added to the obtained sections, and the sections were dyed and observed by an optical microscope.
  • H & E Hematoxylin & Eosin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Selon la présente invention, la poudre d'écorce primaire d'orme ou de racine d'Ulmus davidiana peut s'utiliser pour le traitement des plaies et pour la régénération de la peau, étant donné qu'il s'avère que la poudre favorise la formation de kératinocytes, fait proliférer les tissus épidermique et dermique, stimule la synthèse de collagène du derme, et présente une forte capacité d'absorption de l'eau lui permettant d'absorber les exsudats provenant de plaies dans des modèles de lignées cellulaires et des modèles animaux.
PCT/KR2018/001386 2017-02-01 2018-02-01 Composition pharmaceutique comprenant comme principe actif de la poudre d'écorce primaire d'orme ou de racine d'ulmus davidiana afin de traiter des plaies et de régénérer la peau WO2018143692A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0014658 2017-02-01
KR20170014658 2017-02-01

Publications (1)

Publication Number Publication Date
WO2018143692A1 true WO2018143692A1 (fr) 2018-08-09

Family

ID=63039902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/001386 WO2018143692A1 (fr) 2017-02-01 2018-02-01 Composition pharmaceutique comprenant comme principe actif de la poudre d'écorce primaire d'orme ou de racine d'ulmus davidiana afin de traiter des plaies et de régénérer la peau

Country Status (2)

Country Link
KR (1) KR102026409B1 (fr)
WO (1) WO2018143692A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102325530B1 (ko) 2019-07-17 2021-11-12 풍림무약주식회사 느릅나무로부터 분리한 신규 화합물
KR102333879B1 (ko) 2019-11-12 2021-12-03 주식회사 네이처텍 왕느릅나무 및 모링가의 혼합추출물을 유효성분으로 포함하는 고지혈증 개선용 건강식품 조성물 및 그 제조방법
KR20220001026A (ko) 2020-06-26 2022-01-05 안인숙 산세베리아 추출물을 함유하는 피부재생 및 흉터개선용 외용제 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000060500A (ko) * 1999-03-16 2000-10-16 성재갑 유백피 점액질을 함유하는 피부건조방지용 보습화장료 및 화장비누 조성물
KR20040050154A (ko) * 2002-12-09 2004-06-16 성인영 유근피 추출물 함유 상처 치료용 조성물
KR100439939B1 (ko) * 2001-10-04 2004-07-12 네비온 주식회사 유근피 추출물을 함유하는 항노화 화장품 조성물
KR20130093820A (ko) * 2012-01-18 2013-08-23 (재)예수병원유지재단 피부치료용 느릅나무 추출액, 이를 포함하는 연고 및 밴드 제조방법
KR20130139072A (ko) * 2012-06-12 2013-12-20 네비온 주식회사 불가사리 추출물 및 유근피 추출물을 유효성분으로 함유하는 피부 세포 성장 촉진 효과, 주름개선 효과, 콜라겐 합성 촉진 효과 및 보습 효과를 가지는 화장료 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100828107B1 (ko) * 2006-09-29 2008-05-08 주식회사 코스트리 저백피 추출물을 함유하는 화장료 조성물
KR101379657B1 (ko) 2011-11-30 2014-04-02 주식회사 바이오포트코리아 유근피 추출물을 유효성분으로 포함하는 비만의 예방 및 치료용 조성물
KR20130140378A (ko) * 2012-06-14 2013-12-24 대한민국(농촌진흥청장) 민들레 추출물을 포함하는 피부 노화 방지용 화장료 조성물
KR101738156B1 (ko) * 2015-07-30 2017-05-24 (주)새롬바이오 유근피 추출물을 포함하며, 자외선으로부터의 피부 보호능을 갖는 화장료 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000060500A (ko) * 1999-03-16 2000-10-16 성재갑 유백피 점액질을 함유하는 피부건조방지용 보습화장료 및 화장비누 조성물
KR100439939B1 (ko) * 2001-10-04 2004-07-12 네비온 주식회사 유근피 추출물을 함유하는 항노화 화장품 조성물
KR20040050154A (ko) * 2002-12-09 2004-06-16 성인영 유근피 추출물 함유 상처 치료용 조성물
KR20130093820A (ko) * 2012-01-18 2013-08-23 (재)예수병원유지재단 피부치료용 느릅나무 추출액, 이를 포함하는 연고 및 밴드 제조방법
KR20130139072A (ko) * 2012-06-12 2013-12-20 네비온 주식회사 불가사리 추출물 및 유근피 추출물을 유효성분으로 함유하는 피부 세포 성장 촉진 효과, 주름개선 효과, 콜라겐 합성 촉진 효과 및 보습 효과를 가지는 화장료 조성물

Also Published As

Publication number Publication date
KR20180089872A (ko) 2018-08-09
KR102026409B1 (ko) 2019-09-27

Similar Documents

Publication Publication Date Title
WO2016167527A1 (fr) Composition cosmétique pour la régénération de la peau et composition pharmaceutique pour le traitement des plaies qui contiennent de l'acide sinapique, lequel constitue un composant caractéristique d'extraits de cynanchum atratum, ou des extraits de cynanchum atratum contenant celui-ci
CN101778620B (zh) 紧实和提拉皮肤的组合物及使用方法
JP5042239B2 (ja) コウライシャラノキ抽出物及びその用途
WO2021103581A1 (fr) Composition topique pour la peau ayant une efficacité de promotion de la cicatrisation des plaies et/ou de la réparation des cicatrices
KR101932668B1 (ko) 쉬나무 추출물을 유효성분으로 하는 창상 치유용 약학 조성물
WO2018143692A1 (fr) Composition pharmaceutique comprenant comme principe actif de la poudre d'écorce primaire d'orme ou de racine d'ulmus davidiana afin de traiter des plaies et de régénérer la peau
JP2009517345A (ja) 創傷治癒の方法
WO2021107706A1 (fr) Nouvelle utilisation d'exosomes du lait
WO2013089449A1 (fr) Composition cosmétique contenant la pellicule biologique d'escargots nourris avec du ginseng rouge et procédé de fabrication de cette composition
WO2019027132A1 (fr) Composition pour prévention ou traitement des cicatrices
KR102248258B1 (ko) 녹차 식물세포 유래 엑소좀을 유효성분으로 포함하는 피부개선용 조성물
KR20120014574A (ko) 상처, 피부 질환 및 모발 상실을 치유하기 위한 비그나 마리나 (Ｖｉｇｎａｍａｒｉｎａ), 종려나무과 (Ｃｏｃｏｓ ｎｕｃｉｆｅｒａ Ｌ.), 또는 인디안 아몬드 (Ｔｅｒｍｉｎａｌｉａ ｃａｔａｐｐａ Ｌ.)중에서 한 가지 이상의 추출물
US6589540B1 (en) Cosmetic composition for skin care containing retinol and epidermal growth factor
KR102189330B1 (ko) 구근추출물을 포함하는 피부 개선용 조성물
KR101359720B1 (ko) 마유 및 동백나무 열매 추출물의 혼합물을 함유하는 주름 개선 또는 피부재생 촉진용 조성물
WO2019245332A1 (fr) Composition pharmaceutique pour traiter une plaie ou activer la peau, contenant du bêta-glucane, de la glycitine et de la 4', 6,7-triméthoxyisoflavone
KR101876617B1 (ko) 호랑가시나무 추출물을 함유하는 지방세포 분화 촉진용 조성물
DE60008077T2 (de) Matrixproteinzusammensetzungen um Apoptose zu induzieren
KR102052107B1 (ko) 화장료 조성물
WO2021002561A1 (fr) Micro-aiguille contenant un extrait de symplocarpus foetidus
KR101393813B1 (ko) 체모 성장 억제용 조성물
KR101940787B1 (ko) 진세노사이드 Rb3를 포함하는 줄기세포 배양용 배지에서 배양하여 수득된 배양액을 포함하는 상처 치료용 조성물
KR20140114709A (ko) 좀깨잎나무 추출물을 포함하는 피부 상태 개선용 조성물
WO2023092926A1 (fr) Nouveau polypeptide pour favoriser la réparation tissulaire et son utilisation
KR102109828B1 (ko) 화장료 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18748755

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18748755

Country of ref document: EP

Kind code of ref document: A1